Genedx Holdings Corp. · NASDAQ:WGS
Genedx — Sema4 Holdings — Q3 2021 Earnings Presentation
12 slides from Genedx's earnings presentation, Nov 15, 2021
Slide 1: Third Quarter 2021 Earnings Presentation
1 Third Quarter 2021 Earnings Presentation Exhibit 99.2
Slide 2: Disclaimer
2 Disclaimer This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, fo
Slide 3: Corporate Snapshot
3 ~1,150 Employees 160+ PhD’s1 Guiding to $201- 204mn in total revenue for 2021 Generating and managing 39+ petabytes of data per month Database contains 12 million de-identified clinical records, >500,000 with genomic profiles Accessioning > 250,0002 Next Generation Sequencing tests annually Corpor
Slide 4: Business Highlights
4 Business Highlights 3Q211 YoY revenue growth of 17%, excluding COVID-19 tests 3Q YoY increase of 36% in diagnostics tests resulted2 Launched Sema4 Elements™, our portfolio of data science-driven products and services to support reproductive and generational health Further strengthened C-suite benc
Slide 5: Third Quarter GAAP Financial Highlights
5 Third Quarter GAAP Financial Highlights 3Q 2020 3Q 2021 Total Revenue $38.6 $43.2 GAAP Net Profit ($56.6) $31.42 Gross Profit $2.1 ($15.6) Gross Margin 5% (36%) 1 3 months ended 9/30/21 2 Net profit of $31.4 million included $122.2 million of other income recorded from change in fair market value
Slide 6: Third Quarter Non-GAAP Financial Highlights
6 Third Quarter Non-GAAP Financial Highlights 3Q 2020 3Q 2021 Total Adjusted EBITDA2 ($23.5) ($65.9) Adjusted Gross Profit3 $5.6 ($11.9) Adjusted Gross Margin4 14% (28%) 3Q 20211 – Financial Highlights USD Millions 3Q 2021 – Segment Mix % Revenue 1 3 months ended 9/30/21 2 Adjusted EBITDA is a non-G
Slide 7: NorthShore: The first six months
7 NorthShore: The first six months
Slide 8: Accessioned volume growth has accelerated since early September
8 Accessioned volume growth has accelerated since early September 1 Represents accessioned volume excluding COVID-19 Accessioned volume1 3,500 4,000 4,500 5,000 5,500 6,000 6,500 7,000 1/ 7/ 21 1/ 21 / 21 2/ 4/ 21 2/ 18 / 21 3/ 4/ 21 3/ 18 / 21 4/ 1/ 21 4/ 15 / 21 4/ 29 / 21 5/ 13 / 21 5/ 27 / 21 6
Slide 9: Appendix
Xx se} = O Oo oO <
Slide 10: Historical Revenue Mix
10 Historical Revenue Mix % of Total Revenue1 1Q20 2Q20 3Q20 FY20 1Q21 2Q21 3Q21 Diagnostic Test 99% 93% 84% 79% 73% 87% 86% COVID 0% 6% 14% 18% 25% 8% 10% Other 1% 1% 2% 2% 2% 4% 4% 1 Certain periods do not add to 100% due to rounding
Slide 11: Non-GAAP Gross Margin Reconciliation
11 Non-GAAP Gross Margin Reconciliation USD Millions
Slide 12: Non-GAAP EBITDA Reconciliation
12 Non-GAAP EBITDA Reconciliation USD Millions